Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$38.47 - $42.24 $34,623 - $38,016
900 Added 180.0%
1,400 $54,000
Q2 2024

Aug 14, 2024

BUY
$25.39 - $42.1 $7,617 - $12,630
300 Added 150.0%
500 $21,000
Q1 2024

May 15, 2024

BUY
$27.44 - $35.56 $2,744 - $3,556
100 Added 100.0%
200 $5,000
Q4 2023

Feb 14, 2024

SELL
$28.47 - $38.49 $8,541 - $11,547
-300 Reduced 75.0%
100 $3,000
Q3 2023

Nov 14, 2023

SELL
$28.28 - $38.36 $65,044 - $88,228
-2,300 Reduced 85.19%
400 $12,000
Q2 2023

Aug 14, 2023

SELL
$17.67 - $31.31 $102,486 - $181,598
-5,800 Reduced 68.24%
2,700 $84,000
Q1 2023

May 15, 2023

BUY
$17.13 - $38.52 $56,529 - $127,116
3,300 Added 63.46%
8,500 $193,000
Q4 2022

Feb 14, 2023

BUY
$29.44 - $37.31 $153,088 - $194,012
5,200 New
5,200 $177,000

Others Institutions Holding SRDX

About SURMODICS INC


  • Ticker SRDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 14,005,000
  • Market Cap $554M
  • Description
  • Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device s...
More about SRDX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.